| MSD Merck Sharp & Dohme AG - OncoTICE, Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | 52563 | | 01 | | OncoTICE | | Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | L03AX03 | | Bcg Vaccine | | 16.11.1994 | | |
| | Composition | | Praeparatio cryodesiccata: bacillus Calmette-Guérin (BCG) vivus attenuatum (TICE) 200 - 800 Million CFU, lactosum monohydricum, asparaginum monohydricum, acidum citricum monohydricum, dikalii phosphas anhydricus, magnesii sulfas heptahydricus, ammonii ferri citras, glycerolum, ammonii hydroxidum, zinci formicas, pro vitro. | | Packungsbestandteile | | Praeparatio cryodesiccata: | | | Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | | | | | | | Active Agent | Dose |
|---|
| Bacillus Calmette-Guérin (Bcg) Vivus Attenuatum (Tice) | 200-800 |
| | BAG: Active Agent | Dose |
|---|
| Bacillus Calmette Guerin (Bcg, Tice) | 500 Mio U |
| | | | Inactive agents |
|---|
| Citric Acid Monohydrate | | Ammonii Ferri Citras | | Ammonii Hydroxidum | | Asparaginum Monohydricum | | Dipotassium Phosphate Anhydrate | | Glycerol | | Lactose Monohydrate | | Magnesium Sulfate Heptahydrate | | Million Cfu | | Zinci Formicas |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 038 | Durchstechflasche(n) | 97.53 | 122.50 | A | SL | No |
|
|
